The Senate Judiciary Committee today passed four bills aimed at lowering prescription drug costs and increasing competition.

  • The Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act (S. 1224) would make it illegal for drug makers to use “sham” citizen petitions to delay or keep low-cost generic competitors off the market.
  •  The Prescription Pricing for the People Act (S. 1227) would require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations.
  •  The Preserving Access to Cost Effective Drugs Act (S. 440) would prohibit patent owners from asserting sovereign immunity as a defense in certain actions before the U.S. Patent and Trademark Office to prevent production of generic medications.
  •  The Affordable Prescriptions for Patients Act (S. 1416) would amend the FTC Act to prohibit anticompetitive behaviors by drug product manufacturers, among other provisions. 

These bills could be combined with drug pricing proposals from the Senate Health, Education, Labor and Pensions Committee and Senate Finance Committee. 

Related News Articles

Headline
List prices for branded pharmaceutical products in the United States increased 159% between 2007 and 2018, an average of 9.1% per year, according to a study…
Headline
Four drugs used in hospitals for years increased their prices between 525% and 1,644% after receiving formal approval through the Food and Drug Administration’…
Headline
The Food and Drug Administration today approved the first generic albuterol sulfate inhaler to treat and prevent bronchospasms in patients with asthma or…
Headline
The Food and Drug Administration today released the first phase of its searchable Purple Book database, which includes all FDA-approved biosimilar and…
Headline
The House Ways and Means Health Subcommittee yesterday held a hearing on proposals to lower drug prices and promote new cures.  Witness Ge Bai, an…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…